Savara Inc.

Canaccord Genuity acts as financial advisor to Savara Inc. on its merger with Mast Therapeutics, Inc.

Canaccord Genuity is pleased to announce that on April 27, 2017, Savara Inc., a privately held emerging specialty pharmaceutical company focused on the treatment of rare respiratory diseases, announced the closing of its previously announced merger with Mast Therapeutics, Inc. (NYSE:MSTX), under which the stockholders of Savara have become the majority owners of Mast, and the operations of Mast and Savara have combined.

Canaccord Genuity acted as financial advisor to Savara Inc. and its Board of Directors in connection with the transaction.

Savara Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Savara's pipeline comprises AeroVanc, a Phase 3 ready inhaled vancomycin, Molgradex, a Phase 2/3 stage inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF and Aironite, an inhaled nebulized sodium nitrite solution to treat HFpEF.